Serum oxidative stress level correlates with clinical parameters in chronic systolic heart failure patients

Clinical Cardiology

Volumn 32, Issue 4, 2009, Pages 199-203

  Amir, Offer ^a   Paz, Hagar ^b,c   Rogowski, Ori ^b,c   Barshai, Marina ^c   Sagiv, Moran ^d   Shnizer, Sergei ^e   Reznick, Abraham Z ^c   Amir, Ruthie E ^a,d  

^a CARMEL MEDICAL CENTER   (Israel)

^b Lin Medical Center   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d WINGATE INSTITUTE   (Israel)

^e Lumitest Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; UREA;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEART EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROGNOSIS; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; SYSTOLIC HEART FAILURE; UREA BLOOD LEVEL;

AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 64949152719     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20317     Document Type: Article

References (29)

1. Valgimigli M, Merli E, Malagutti P, et al. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;43:2000-2008.
2. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48:992-998.
3. Li Y, Takemura G, Okada H, et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res. 2006;71:684-694.
4. Pacher P, Schulz R, Liaudet L, Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci. 2005;26:302-310.
5. Jonsson G, Abdelnoor M, Seljeflot I, et al. The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. J Cardiovasc Pharmacol. 2007;49:27-32.
6. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens. 2007;25:785-791.
7. Shnizer S, Kagan T, Lanir A, Maor I, Reznick AZ. Modifications and oxidation of lipids and proteins in human serum detected by thermochemiluminescence. Luminescence. 2003;18:90-96.
8. Reznick AZ, Brook G, Hochman A, et al. Thermocemiluminescence (TCL) oxidizability assay-clinical laboratory studies. In: Osben T, Chevion M, eds. NATO Science Series: Frontiers in Neurodegenerative Diseases and Aging: Fundamental Aspects, Clinical Perspectives and New Insights. Series I: Life and Behavioral Sciences. Amsterdam, The Netherlands: IOS Press; 2004; 40-55.
9. Lissak A, Wiener-Megnazi Z, Reznick AZ, et al. Oxidative stress indices in seminal plasma, as measured by the thermochemiluminescence assay, correlate with sperm parameters. Fertil Steril. 2004;81:792-797.
10. Wiener-Megnazi Z, Vardi L, Lissak A, et al. Oxidative stress indices in follicular fluid as measured by the thermochemiluminescence assay correlate with outcome parameters in vitro fertilization. Fertil Steril. 2004;82:1171-1176.
11. van den Broek SA, van Veldhuisen DJ, de Graeff PA, et al. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;70:359-363.
12. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
13. Hillege HL, Nitsch D, Pfeffer MA, etal. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678.
14. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352: 666-675.
15. Nonaka-Sarukawa M, Yamamoto K, Aoki H, et al. Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart. 2003; 89:871-874.
16. Hokamaki J, Kawano H, Yoshimura M, et al. Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol. 2004;43:1880-1885.
17. Wijeysundera HC, Hansen MS, Stanton E, et al. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J. 2003;146:291-297.
18. Ellis GR, Anderson RA, Lang D, etal. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy. J Am Coll Cardiol. 2000;36:1474-1482.
19. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601-623.
20. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res. 2001;49:798-807.
21. Long X, Goldenthal MJ, Wu GM, Marin-Garcia J. Mitochondrial Ca2+ flux and respiratory enzyme activity decline are early events in cardiomyocyte response to H2O2. J Mol Cell Cardiol. 2004;37:63-70.
22. Tsutsui H. Mitochondrial oxidative stress and heart failure. Intern Med. 2006;45:809-813.
23. Mallat Z, Philip I, Lebret M, etal. Elevated levels of 8-isoprostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998;97: 1536-1539.
24. Kameda K, Matsunaga T, Abe N, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J. 2003;24:2180-2185.
25. Ferrari R, Guardigli G, Mele D, etal. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm. 2004;10: 1699-1711.
26. Boger RH, Schwedhelm E, Maas R, Quispe-Bravo S, Skamira C. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. Vasc Med. 2005;10:S97-S102.
27. Domenici FA, Vannucchi MT, Jordao AA Jr, Meirelles MS, Vannucchi H. DNA oxidative damage in patients with dialysis reatment. Ren Fail. 2005;27:689-694.
28. Cottone S, Palermo A, Vaccaro F, etal. In renal transplanted patients inflammation and oxidative stress are interrelated. Transplant Proc. 2006;38:1026-1030.
29. Abrams J. C-reactive protein, inflammation, and coronary risk: an update. Cardiol Clin. 2003;21:327-331.